Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Sanofi Announces Auvi-Q™, the First and Only Voice-Guided Epinephrine Auto-Injector, is Now Available in the U.S.


PR Newswire/Les Echos/

PRESS RELEASE


                Sanofi Announces Auvi-Q(TM), the First and Only 
                     Voice-Guided Epinephrine Auto-Injector, 
                          is Now Available in the U.S.
         -- Breakthrough device design talks patients and caregivers 
                         through the injection process --

Paris, France - January 28, 2013 - Sanofi (EURONEXT : SAN and NYSE : SNY)
announced today that Auvi-Q(TM) (epinephrine injection, USP) is now available 
in U.S. retail pharmacies nationwide with a prescription from a healthcare
provider.

Auvi-Q is the first-and-only epinephrine auto-injector with audio and visual
cues for the emergency treatment of life-threatening allergic reactions in
people who are at risk for or have a history of anaphylaxis.(1) The size and
shape of a credit card and the thickness of a smart phone, Auvi-Q is a
breakthrough in epinephrine auto-injector device design that talks patients 
and caregivers step-by-step through the injection process.

"Patient feedback was a critical component to the development process for
Auvi-Q," said Anne Whitaker, President, North America Pharmaceuticals, Sanofi.
"The availability of Auvi-Q represents an important step forward in our
continued innovation to meet the needs of people at risk for anaphylaxis and
their caregivers."

Up to six million Americans may be at risk for anaphylaxis, although the 
precise incidence is unknown and likely underreported. While guidelines 
emphasize the importance of the life-saving role of epinephrine, two large 
surveys (n=600 and n=651) show that two-thirds of patients and caregivers do 
not carry their epinephrine auto-injectors as recommended, and nearly half 
worry that others will not know how to use their or their child's epinephrine 
auto-injector correctly during an emergency. Multiple studies have found an 
association between delay in epinephrine administration and death from 
anaphylaxis.

Life-threatening allergic reactions may occur as a result of exposure to
allergens including foods such as peanuts, tree nuts, fish, shellfish, dairy,
eggs, soy and wheat; insect stings; latex and medication, among other 
allergens and causes.

About Auvi-Q

Auvi-Q provides users with audible and visual cues, including a five-second
injection countdown and an alert light to signal when the injection is complete
Auvi-Q also features an automatic retractable needle mechanism to help prevent
accidental needle sticks.

Available in two different dosages, Auvi-Q 0.3mg delivers 0.3mg epinephrine
injection and is intended for patients who weigh 66 pounds or more. Auvi-Q
0.15mg delivers 0.15mg epinephrine injection and is intended for patients who
weigh 33 - 66 pounds. Auvi-Q has not been studied in patients weighing less 
than 33 pounds. Each Auvi-Q pack contains two devices - containing one dose of
epinephrine each - and a non-active training device. Auvi-Q received U.S. Food
and Drug Administration approval in August 2012.

Sanofi US licensed the North America commercialization rights to Auvi-Q from
Intelliject, Inc., which has retained commercialization rights for the rest of
the world. Eric and Evan Edwards, twin brothers who suffer from 
life-threatening allergies, and co-founders of Intelliject, Inc., developed 
Auvi-Q with a team of world class engineers and scientists. The development 
process incorporated real-world experiences and feedback from patients and 
caregivers.

Auvi-Q has been named an International CES Innovations 2013 Design and
Engineering Awards Honoree. The prestigious Innovations Design and Engineering
Awards are sponsored by the Consumer Electronics Association (CEA)(r), the
producer of the International CES and the world's largest consumer technology
tradeshow. http://www.cesweb.org/Awards/CES-Innovations-Awards.aspx

About Anaphylaxis
The signs and symptoms of anaphylaxis can vary from person to person and from
one episode to the next. Some people may have hives/itching, facial or tongue
swelling, which makes it difficult to breathe or swallow, while others may
experience nausea and vomiting. These symptoms may begin within seconds, 
minutes or hours after exposure to the allergen. The best prevention method 
for anaphylaxis is avoidance of the specific allergen(s).

When a severe, life-threatening allergic reaction occurs, epinephrine should 
be administered immediately and patients and caregivers should seek immediate
medical attention. Patients and caregivers should always carry and know how to
use an epinephrine auto-injector to treat emergency allergic reactions. Without
treatment, anaphylaxis can result in death within a matter of minutes.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, rare diseases, consumer 
healthcare, emerging markets and animal health. Sanofi is listed in Paris 
(EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi is the holding company of a consolidated group of subsidiaries and
operates in the United States as Sanofi US, also referred to as Sanofi-aventis
U.S. LLC. For more information on Sanofi US, please visit http://www.sanofi.us
or call 1-800-981-2491.

Forward Looking Statements

This press release contains forward-looking statements as defined in the 
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking 
statements are statements that are not historical facts. These statements 
include projections and estimates and their underlying assumptions, statements 
regarding plans, objectives, intentions and expectations with respect to 
future financial results, events, operations, services, product development 
and potential, and statements regarding future performance. Forward-looking 
statements are generally identified by the words "expects", "anticipates", 
"believes", "intends", "estimates", "plans" and similar expressions. Although 
Sanofi's management believes that the expectations reflected in such 
forward-looking statements are reasonable, investors are cautioned that 
forward-looking information and statements are subject to various risks and 
uncertainties, many of which are difficult to predict and generally beyond the 
control of Sanofi, that could cause actual results and developments to differ 
materially from those expressed in, or implied or projected by, the 
forward-looking information and statements. These risks and uncertainties 
include among other things, the uncertainties inherent in research and 
development, future clinical data and analysis, including post marketing, 
decisions by regulatory authorities, such as the FDA or the EMA, regarding 
whether and when to approve any drug, device or biological application that 
may be filed for any such product candidates as well as their decisions 
regarding labelling and other matters that could affect the availability or 
commercial potential of such product candidates, the absence of guarantee that 
the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's 
ability to benefit from external growth opportunities, trends in exchange 
rates and prevailing interest rates, the impact of cost containment policies 
and subsequent changes thereto, the average number of shares outstanding as 
well as those discussed or identified in the public filings with the SEC and 
the AMF made by Sanofi, including those listed under "Risk Factors" and 
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual 
report on Form 20-F for the year ended December 31, 2011. Other than as 
required by applicable law, Sanofi does not undertake any obligation to update 
or revise any forward-looking information or statements.

Contacts: 

Sanofi

Media Relations                         Investor Relations

Marisol Péron                           Sébastien Martel
Tel. : + (33) 1 53 77 45 02             Tel. : + (33) 1 53 77 45 45
marisol.peron@sanofi.com                ir@sanofi.com

Jack Cox                                George Grofik
Tel.: +1 908 981 5280                   Tel.: +1 908 981 6031
jack.cox@sanofi.com                     george.grofik@sanofi.com

Lori Lukus
Tel: +1 908 981 3876 
lori.lukus@sanofi.com

(1) Auvi-Q PI. Section 1. Indications and Use

The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.

-0- Jan/28/2013 13:30 GMT

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement